STAT

From ferrets to mice and marmosets, labs scramble to find right animals for coronavirus studies

Labs can’t use just any animal to test a #Covid19 vaccine or drug. Not every animal is susceptible to the #coronavirus, and those that are may not show signs of…
Ferrets are among the animals researchers are infecting with the Covid-19 virus as they search for a suitable species to use in tests of vaccines and drugs.

One lab is digging into its freezer to thaw out the archived sperm of SARS-susceptible mice. Another is anesthetizing ferrets so they don’t sneeze when the new coronavirus is squirted into their nostrils. Yet others are racing to infect macaques, marmosets, and African green monkeys.

Those animals could prove critical for understanding how Covid-19 works — and for concocting vaccines and treatments to stop its sweep. Every day, it seems another company announces an attempt to make its own virus-fighting vials. But to test an experimental formulation, scientists can’t just jump from Petri dishes into people. They need to try it in critters first, to check that the stuff is safe and effective.

Now, researchers are rushing to figure out which creatures work best, a task that could take months. “We’re at the ‘Uh oh, it’s complicated’ stage,” said Lisa Gralinski, a microbiologist and assistant professor of epidemiology who studies coronaviruses at the University of North Carolina at Chapel Hill.

The trouble is, labs can’t just use whatever animal they have lying around to start

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.

Related Books & Audiobooks